Spectral AI, Inc. (MDAI)

Spectral AI, Inc. (MDAI) Healthcare & Pipeline Overview

Spectral AI, Inc. leverages artificial intelligence to revolutionize wound care diagnostics with its DeepView system. Targeting improved treatment outcomes for burn and diabetic foot ulcer patients, the company offers clinicians an objective assessment of healing potential, differentiating itself through AI-driven predictive capabilities in the medical device sector.

What Is the Investment Thesis for MDAI?

Spectral AI, Inc. presents a notable research candidate within the medical device sector, driven by its innovative DeepView technology. The company's focus on AI-powered wound care diagnostics addresses a significant market need, particularly in the treatment of burns and diabetic foot ulcers. With a market capitalization of $59.51M, Spectral AI offers potential for substantial growth as it expands its market presence and secures regulatory approvals. The company's gross margin of 44.4% indicates a solid foundation for profitability as revenue scales. Key catalysts include ongoing clinical trials and potential partnerships with healthcare providers. However, the company's negative profit margin of -41.1% highlights the need for efficient cost management and revenue growth to achieve sustainable profitability. Monitoring the company's ability to secure additional funding and navigate regulatory hurdles will be crucial for assessing its long-term investment viability.

Based on FMP financials and quantitative analysis

MDAI Key Highlights

• Market capitalization of $59.51M reflects the company's current valuation in the market.
• Gross margin of 44.4% indicates the profitability of the company's core product, DeepView.
• Profit margin of -41.1% highlights the current challenges in achieving overall profitability.
• Beta of 0.91 suggests that the stock's volatility is slightly lower than the market average.
• Focus on AI-driven wound care diagnostics positions the company in a high-growth area of the medical device industry.

Who Are MDAI's Competitors?

MDAI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are MDAI's Key Strengths?

• Innovative AI-driven DeepView technology.
• Focus on unmet needs in wound care.
• Potential for improved patient outcomes and reduced healthcare costs.

What Are MDAI's Weaknesses?

• Limited market presence and brand recognition.
• Reliance on a single product (DeepView).
• Negative profit margin.

What Could Drive MDAI Stock Higher?

• Publication of clinical trial results demonstrating the efficacy of DeepView.
• Strategic partnerships with hospitals and wound care centers.
• Expansion of DeepView's applications to other wound types.

What Are the Key Risks for MDAI?

• Financial-distress signal — its Altman Z-Score of -5.24 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Competition from established medical device companies.
• Regulatory hurdles and reimbursement challenges.
• Need for additional funding to support growth initiatives.

What Are the Growth Opportunities for MDAI?

• Expansion into Diabetic Foot Ulcer Market: The diabetic foot ulcer (DFU) market represents a significant growth opportunity for Spectral AI. The global DFU treatment market is projected to reach $11.3 billion by 2027, driven by the rising prevalence of diabetes. Spectral AI's DeepView technology can provide clinicians with valuable insights into wound healing potential, leading to improved treatment outcomes and reduced healthcare costs. Successfully penetrating this market will require strategic partnerships with diabetes clinics and hospitals.
• Strategic Partnerships with Healthcare Providers: Forming strategic partnerships with hospitals, wound care centers, and other healthcare providers can accelerate the adoption of Spectral AI's DeepView technology. These partnerships can provide access to a broader patient base and facilitate the integration of DeepView into existing clinical workflows. The company should focus on demonstrating the clinical and economic benefits of DeepView to potential partners, highlighting its ability to improve patient outcomes and reduce healthcare costs.
• Geographic Expansion into International Markets: Expanding into international markets represents a significant growth opportunity for Spectral AI. The global wound care market is experiencing growth in regions such as Europe and Asia-Pacific. Spectral AI can leverage its DeepView technology to address the unmet needs in these markets, particularly in countries with aging populations and high rates of diabetes. Successful international expansion will require adapting the company's marketing and sales strategies to local market conditions.
• Development of New AI-Powered Diagnostic Tools: Spectral AI can leverage its expertise in artificial intelligence to develop new diagnostic tools for other medical conditions. This can expand the company's product portfolio and address a broader range of healthcare needs. Potential areas for expansion include diagnostics for cardiovascular disease, cancer, and other chronic conditions. Investing in research and development will be crucial for driving innovation and maintaining a competitive edge.
• Securing Regulatory Approvals and Reimbursement: Obtaining regulatory approvals and securing reimbursement for DeepView are critical for driving adoption and revenue growth. Spectral AI should focus on demonstrating the clinical and economic value of DeepView to regulatory agencies and payers. This will require conducting clinical trials and generating data to support the company's claims. Successfully navigating the regulatory and reimbursement landscape will be essential for realizing the full potential of DeepView.

What Opportunities Does MDAI Have?

• Expansion into diabetic foot ulcer market.
• Strategic partnerships with healthcare providers.
• Geographic expansion into international markets.

What Threats Does MDAI Face?

• Competition from established medical device companies.
• Regulatory hurdles and reimbursement challenges.
• Potential for technological obsolescence.

What Are MDAI's Competitive Advantages?

• Proprietary AI algorithms for wound healing prediction.
• First-mover advantage in AI-driven wound care diagnostics.
• Growing database of wound images and clinical data to improve AI accuracy.

What Does MDAI Do?

Spectral AI, Inc., based in Dallas, Texas, is an artificial intelligence company focused on transforming medical diagnostics in wound care. The company's core mission is to provide faster and more accurate treatment decisions for patients suffering from burns and diabetic foot ulcers. Spectral AI's flagship product, DeepView, is a predictive diagnostic device that offers clinicians an objective and immediate assessment of a wound's healing potential before any treatment or medical intervention is initiated. This technology aims to reduce uncertainty in wound management, leading to better patient outcomes and reduced healthcare costs. Founded with the vision of applying advanced AI to solve critical healthcare challenges, Spectral AI has positioned itself at the intersection of artificial intelligence and medical devices. The DeepView system represents a significant advancement in wound care, moving away from subjective assessments to data-driven predictions. The company's focus on burns and diabetic foot ulcers addresses significant unmet needs in these patient populations, where timely and effective treatment is crucial for preventing complications and improving quality of life. Spectral AI's geographic reach is currently centered in the United States, with plans for future expansion into other markets.

What Products and Services Does MDAI Offer?

• Develop artificial intelligence (AI) solutions for medical diagnostics.
• Focus on wound care applications, specifically burns and diabetic foot ulcers.
• Offer the DeepView system, a predictive diagnostic device.
• Provide clinicians with objective assessments of wound healing potential.
• Enable faster and more accurate treatment decisions.
• Improve patient outcomes through data-driven insights.

How Does MDAI Make Money?

• Selling the DeepView system to hospitals and wound care centers.
• Generating revenue through per-use fees or subscription models for DeepView.
• Potentially offering data analytics services based on DeepView's diagnostic insights.

What Industry Does MDAI Operate In?

Spectral AI operates within the medical device industry, specifically targeting the wound care market. The global wound care market is experiencing growth, driven by factors such as the increasing prevalence of diabetes and the aging population. The competitive landscape includes established medical device companies and emerging players focused on advanced wound care technologies. Spectral AI differentiates itself through its AI-powered DeepView system, which offers predictive diagnostics for wound healing potential. This positions the company to capitalize on the growing demand for innovative and data-driven solutions in wound care.

Who Are MDAI's Key Customers?

• Hospitals and medical centers.
• Wound care clinics and specialists.
• Burn centers and surgeons.

F-Score 3/9Financial Health

Spectral AI, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -5.24 places it in the distress zone, a signal of elevated financial risk.

ROE 179%Key Financial Metrics

Return on equity for Spectral AI, Inc. stands at 179.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -80.6%, showing how much profit it generates from its asset base. Its free cash flow yield is -21.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.75 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -25.6%, the inverse of the P/E and a quick read on earnings relative to price.

Spectral AI, Inc. (MDAI) Valuation Context

Valued at $59.51M, MDAI is classified as a micro-cap stock. Relative to its peer group, MDAI's quantitative score of 20/100 is below the peer average of 69/100.

FY2026 estForward Outlook

Wall Street analysts project Spectral AI, Inc. revenue of about $18.8M for fiscal 2026, with EPS near $-0.54.

MDAI Financials

MDAI Latest News

MDAI Analyst Consensus

MDAI MoonshotScore

What Investors Ask About Spectral AI, Inc. (MDAI) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources